IMMUNOTHERAPY PANEL (INCLUDED TMB+MSI)

image not found

NABL Cap Accredited     
The Immunotherapy Panel (including TMB and MSI) is a comprehensive genomic profiling test designed to evaluate biomarkers that predict response to cancer immunotherapy. It measures Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI), which help assess the likelihood of benefit from immune checkpoint inhibitor treatments. Metropolis Healthcare performs this advanced analysis using high-precision Next-Generation Sequencing technology to support personalized oncology care and guide treatment decisions. This panel is particularly valuable for patients with solid tumors where immunotherapy is part of the clinical pathway
 

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 45,000.00

Sample Type: null

Fasting Not Required


Notes: I8450

Frequently Asked Questions (FAQ's):

What does the Immunotherapy Panel (TMB + MSI) include?
This test evaluates Tumor Mutational Burden and Microsatellite Instability, key markers that help determine how effectively a patient may respond to immunotherapy.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses advanced Next-Generation Sequencing platforms to analyze tumor tissue with high sensitivity and reliability.

Who should take this test?
Cancer patients being considered for immunotherapy or those with recurrent, metastatic, or treatment-resistant tumors are ideal candidates.

What sample is required for this test?
FFPE tumor tissue blocks or tissue slides are required for processing at Metropolis Healthcare.

How do TMB and MSI results support treatment planning?
High TMB or MSI-High status indicates better response potential to immune checkpoint inhibitors like PD-1, PD-L1, or CTLA-4 targeted therapies.

How long do results take at Metropolis Healthcare?
Typically, results are available within 12–15 working days depending on sample complexity.

Is this test useful for all types of cancers?
Yes, it is valuable across a broad range of solid tumors including colorectal, lung, gastric, breast, and endometrial cancers.

Does Metropolis Healthcare offer related genomic testing?
Yes, Metropolis Healthcare provides extensive genomic oncology panels including HRD Score, Liquid Biopsy NGS, and comprehensive somatic mutation profiling

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab